Cargando…
Immune Cytolytic Activity for Comprehensive Insights of the Immune Landscape in Endometrial Carcinoma
Immune checkpoint blockade (ICB) has been explored as a therapeutic strategy to recover the antitumor immune activities against endometrial cancer (EC) escaping from immune surveillance. Increasing evidence has indicated that microsatellite instability (MSI) is a promising biomarker to stratify pati...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313908/ https://www.ncbi.nlm.nih.gov/pubmed/35898926 http://dx.doi.org/10.1155/2022/9060243 |
_version_ | 1784754189838057472 |
---|---|
author | Chen, Qiang Wang, Chongyang Lei, Xinyi Huang, Ting Zhou, Renyu Lu, Yuanzhi |
author_facet | Chen, Qiang Wang, Chongyang Lei, Xinyi Huang, Ting Zhou, Renyu Lu, Yuanzhi |
author_sort | Chen, Qiang |
collection | PubMed |
description | Immune checkpoint blockade (ICB) has been explored as a therapeutic strategy to recover the antitumor immune activities against endometrial cancer (EC) escaping from immune surveillance. Increasing evidence has indicated that microsatellite instability (MSI) is a promising biomarker to stratify patients for the ICB therapy. However, even in patients with MSI-High (MSI-H) endometrial cancers, PD-L1 inhibitors, avelumab, and durvalumab have shown only 27% of response rates. Therefore, there is an urgent need to discover new biomarkers for a predictive response to ICB therapy. In this study, we demonstrated that the immune cytolytic activity (CYT) index was significantly correlated with the development and response to immunotherapy in EC. The data showed that higher CYT was significantly associated with better clinical outcome, more antitumor infiltrating immune cells, fewer somatic copy number alterations, but a higher TMB (Tumor mutational burden) status. Furthermore, CYT-high EC was notably relevant to the high expression of various immune checkpoint molecules and showed more effective responses to ICB treatment. Taken together, this study provided new insights into the connection between diverse genetic events and the immune microenvironment in EC and indicated that the CYT status might be a promising biomarker to stratify patients with EC for ICB therapy. |
format | Online Article Text |
id | pubmed-9313908 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-93139082022-07-26 Immune Cytolytic Activity for Comprehensive Insights of the Immune Landscape in Endometrial Carcinoma Chen, Qiang Wang, Chongyang Lei, Xinyi Huang, Ting Zhou, Renyu Lu, Yuanzhi J Oncol Research Article Immune checkpoint blockade (ICB) has been explored as a therapeutic strategy to recover the antitumor immune activities against endometrial cancer (EC) escaping from immune surveillance. Increasing evidence has indicated that microsatellite instability (MSI) is a promising biomarker to stratify patients for the ICB therapy. However, even in patients with MSI-High (MSI-H) endometrial cancers, PD-L1 inhibitors, avelumab, and durvalumab have shown only 27% of response rates. Therefore, there is an urgent need to discover new biomarkers for a predictive response to ICB therapy. In this study, we demonstrated that the immune cytolytic activity (CYT) index was significantly correlated with the development and response to immunotherapy in EC. The data showed that higher CYT was significantly associated with better clinical outcome, more antitumor infiltrating immune cells, fewer somatic copy number alterations, but a higher TMB (Tumor mutational burden) status. Furthermore, CYT-high EC was notably relevant to the high expression of various immune checkpoint molecules and showed more effective responses to ICB treatment. Taken together, this study provided new insights into the connection between diverse genetic events and the immune microenvironment in EC and indicated that the CYT status might be a promising biomarker to stratify patients with EC for ICB therapy. Hindawi 2022-07-18 /pmc/articles/PMC9313908/ /pubmed/35898926 http://dx.doi.org/10.1155/2022/9060243 Text en Copyright © 2022 Qiang Chen et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Chen, Qiang Wang, Chongyang Lei, Xinyi Huang, Ting Zhou, Renyu Lu, Yuanzhi Immune Cytolytic Activity for Comprehensive Insights of the Immune Landscape in Endometrial Carcinoma |
title | Immune Cytolytic Activity for Comprehensive Insights of the Immune Landscape in Endometrial Carcinoma |
title_full | Immune Cytolytic Activity for Comprehensive Insights of the Immune Landscape in Endometrial Carcinoma |
title_fullStr | Immune Cytolytic Activity for Comprehensive Insights of the Immune Landscape in Endometrial Carcinoma |
title_full_unstemmed | Immune Cytolytic Activity for Comprehensive Insights of the Immune Landscape in Endometrial Carcinoma |
title_short | Immune Cytolytic Activity for Comprehensive Insights of the Immune Landscape in Endometrial Carcinoma |
title_sort | immune cytolytic activity for comprehensive insights of the immune landscape in endometrial carcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313908/ https://www.ncbi.nlm.nih.gov/pubmed/35898926 http://dx.doi.org/10.1155/2022/9060243 |
work_keys_str_mv | AT chenqiang immunecytolyticactivityforcomprehensiveinsightsoftheimmunelandscapeinendometrialcarcinoma AT wangchongyang immunecytolyticactivityforcomprehensiveinsightsoftheimmunelandscapeinendometrialcarcinoma AT leixinyi immunecytolyticactivityforcomprehensiveinsightsoftheimmunelandscapeinendometrialcarcinoma AT huangting immunecytolyticactivityforcomprehensiveinsightsoftheimmunelandscapeinendometrialcarcinoma AT zhourenyu immunecytolyticactivityforcomprehensiveinsightsoftheimmunelandscapeinendometrialcarcinoma AT luyuanzhi immunecytolyticactivityforcomprehensiveinsightsoftheimmunelandscapeinendometrialcarcinoma |